Physician profile
Eldibrando Ramos
NPI 1629571583
$7,420.16
in general payments reported to CMS, 2019-2025
24 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $1,732 · 2023: $1,488 · 2024: $1,605 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,130.68 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $792.53 | 2021-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $444.88 | 2021-2025 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $407.40 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $354.92 | 2021-2024 | Talicia |
| Nestle Healthcare Nutrition INC. | $220.42 | 2021-2023 | |
| Lilly USA, LLC | $198.11 | 2024-2025 | Omvoh, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $197.13 | 2023-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $189.86 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $184.14 | 2021-2024 | Linzess |
| Celgene Corporation | $182.36 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $171.07 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $162.70 | 2021-2025 | Wegovy |
| Madrigal Pharmaceuticals | $134.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $124.66 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $116.31 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $111.06 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $71.08 | 2024-2025 | Iqirvo, Bylvay |
| Novartis Pharmaceuticals Corporation | $62.03 | 2021 | |
| Intercept Pharmaceuticals, INC. | $58.24 | 2021-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $41.33 | 2021-2024 | |
| Vivus LLC | $24.19 | 2021 | |
| Gilead Sciences, INC. | $21.51 | 2025 | |
| Esperion Therapeutics, INC. | $18.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eldibrando Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.